The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
News|Articles|March 1, 1998
Hyperpigmented Plaques
Author(s)Norman Levine, MD
These velvety, hyperpigmented plaques are secondary to acanthosis nigricans, a common problem in patients with insulin-resistant states.
Advertisement
These velvety, hyperpigmented plaques are secondary to acanthosis nigricans, a common problem in patients with insulin-resistant states. Many of these patients have high plasma insulin levels. The condition usually does not abate completely but may improve when diabetes is controlled.
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
2
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
3
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
4
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
5